Article Text

Download PDFPDF

Gabapentin for the treatment of pain manifestations in children with severe neurological impairment: a single-centre retrospective review
  1. Aedin Collins1,
  2. Rory Mannion1,
  3. Annemarie Broderick1,2,
  4. Séamus Hussey1,2,3,
  5. Mary Devins4,
  6. Billy Bourke1,2
  1. 1National Centre for Paediatric Gastroenterology, Hepatology and Nutrition, Children's Health Ireland at Crumlin, Dublin, Ireland
  2. 2National Children’s Research Center and Department of Paediatrics, UCD School of Medicine and Medical Science, Dublin, Ireland
  3. 3Department of Paediatrics, Royal College of Surgeons, Ireland, Dublin, Ireland
  4. 4Department of Paediatric Palliative Care, Children's Health Ireland at Crumlin, Dublin, Ireland
  1. Correspondence to Dr Aedin Collins; aedincollins{at}gmail.com

Abstract

Pain, irritability and feeding intolerance are common symptoms affecting quality of life in children with severe neurological impairment (SNI). We performed a retrospective study to explore the use of gabapentinoid medications for symptom control in children with SNI. Patients attending the palliative care or gastroenterology department being treated with gabapentin for irritability, vomiting or pain of unknown origin were included. Information was gathered retrospectively from medical documentation. Irritability was reduced in 30 of the 42 patients included. Gabapentin was discontinued in 15 children, 12 of whom then received pregabalin. Three children had a good response to pregabalin, six a minimal improvement and three no improvement. These results support the use of gabapentinoids in this patient cohort.

  • general paediatrics
  • neurodisability
  • pain
  • palliative care
  • gastroenterology

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors AC conceptualised and designed the study, designed the data collection instruments, collected the data, drafted the initial manuscript, and reviewed and revised the manuscript. RM designed the study, designed the data collection instruments, collected the data, and reviewed and revised the manuscript. SH and AB conceptualised the study, designed the data collection instruments and critically reviewed the manuscript for important intellectual content. BB and MD conceptualised and designed the study, designed the data collection instruments, carried out the initial analysis, and reviewed and revised the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval Ethical approval was granted by the Research Ethics Committee of Our Lady’s Children’s Hospital, Crumlin.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.